(133) Anticancer activity of extended release loperamide from styrene-isoprene-styrene polymer in vitro
Introduction: Sustained release drug delivery is a wellestablishedstrategy to achieve durable pharmacologic effects. We recently developed styrene-isoprene-styrene (SIS) polymer as a drug release platform that largely retains the mechanical flexibility of the parent polymer, while allowing extended release of a number of drugs.1Here we studied release of loperamide, an over the counteranti-peristaltic treatment for diarrheathat works via peripheral mu opioid receptors. The drug also has anticancer2, 3as well as analgesic activity4and sustained release of loperamide may have clinical utility.
Learning Objectives:
Upon completion, participants will be able to describe the anti-cancer activity of loperamide.
Upon completion, participants will be able to appreciate lasting cytotoxicity from SIS-loperamide.
Upon completion, participants will be able to list two SIS-loperamide eluate sensitive cancers.
Jessica Winakor – Lab Technician, Anesthesiology-Critical Care, Memorial Sloan Kettering Cancer Center; Susan Wang – intern, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center; Rong Wang – Senior Research Assistant, Nuclear Magnetic Resonance (Analytical) Core Facility, Sloan Kettering Institute; George Sukenick – Associate Lab Member, Nuclear Magnetic Resonance (Analytical) Core Facility, Sloan Kettering Institute; Ron Feiner – Equity Research Associate, J.P. Morgan; Declan Gwynne – Senior Associate Scientist, Generation Bio; Gregory Fischer – Chairman Attending, Anesthesiology-Critical Care, Memorial Sloan Kettering Cancer Center; Michael Kharas – Member, Molecular Pharmacology Program, Sloan Kettering Institute; Daniel Heller – Member, Molecular Pharmacology Program, Sloan Kettering Institute
